It’s hard to think of a company that faces a bigger perception gap than Anduril. Talk to investors in Silicon Valley, and they will be clamoring to get in on its next round—last priced at $30 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback